Laboratory assessment of rivaroxaban: a review

Meyer Michel Samama1, Geneviève Contant, Theodore E Spiro

  • 1Hôtel-Dieu University Hospital, 1 place du Paris Notre-Dame, Paris 75004, 4ème, Paris, France. meyermichel.samama@biomnis.com.

Thrombosis Journal
|July 5, 2013
PubMed

Insights

Rivaroxaban, a direct Factor Xa inhibitor, effectively manages thromboembolic disorders with fixed doses. Anti-Factor Xa assays can measure drug levels when needed, but results require careful interpretation alongside patient factors.

Area of Science:

  • Pharmacology
  • Hematology
  • Clinical Medicine

Background:

  • Thromboembolic disorders necessitate effective anticoagulation.
  • Targeting specific coagulation enzymes like Factor Xa offers a therapeutic strategy.
  • Rivaroxaban, a direct Factor Xa inhibitor, has demonstrated efficacy in clinical trials.

Purpose of the Study:

  • To review the role and application of rivaroxaban in managing thromboembolic disorders.
  • To discuss the utility and interpretation of anti-Factor Xa assays for assessing rivaroxaban exposure.
  • To highlight considerations for clinicians when interpreting assay results.

Main Methods:

  • Review of phase III clinical trial data for rivaroxaban.
  • Discussion of pharmacokinetic and pharmacodynamic properties of rivaroxaban.
  • Explanation of anti-Factor Xa chromogenic assays and their calibration.

Main Results:

  • Rivaroxaban is approved for managing several thromboembolic disorders.
  • Fixed-dose regimens are generally used without routine coagulation monitoring.
  • Anti-Factor Xa assays can quantify rivaroxaban levels, aiding exposure assessment.

Conclusions:

  • Rivaroxaban offers a predictable anticoagulant profile suitable for fixed dosing.
  • Interpretation of anti-Factor Xa assay results requires consideration of sampling time and patient-specific bleeding risks.
  • Assays measure drug concentration, not anticoagulant activity intensity, necessitating clinical correlation.

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...